Analysis of RNA m⁶A methylation regulators and tumour immune cell infiltration characterization in prostate cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Damodaran S, Kyriakopoulos CE, Jarrard DF. Newly diagnosed metastatic prostate cancer: has the paradigm changed? Urol Clin North Am. 2017;44(4):611–621.
   PubMed Web of Science ®Google Scholar
• Lo UG, Lee CF, Lee MS, et al. The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression. Int J Mol Sci. 2017;18(10):2079.
   Web of Science ®Google Scholar
• Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014;311(11):1143–1149.
   PubMed Web of Science ®Google Scholar
• Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24(3):511–520.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Liu Q, Liao Q, Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int. 2017;17:68.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.
   PubMed Web of Science ®Google Scholar
• Safonov A, Jiang T, Bianchini G, et al. Immune gene expression is associated with genomic aberrations in breast cancer. Cancer Res. 2017;77(12):3317–3324.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.
   PubMed Web of Science ®Google Scholar
• Perry JK, Kelley DE. Existence of methylated messenger RNA in mouse L cells. Cell. 1974;1(1):37–42.
   Web of Science ®Google Scholar
• Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201–206.
   PubMed Web of Science ®Google Scholar
• Tong J, Flavell RA, Li HB. RNA m6A modification and its function in diseases. Front Med. 2018;12(4):481–489.
   PubMed Web of Science ®Google Scholar
• Han D, Liu J, Chen C, et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270–274.
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330.
   PubMed Web of Science ®Google Scholar
• He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.
   PubMed Web of Science ®Google Scholar
• Dai D, Wang H, Zhu L, et al. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 2018;9(2):124.
   PubMed Web of Science ®Google Scholar
• Li J, Meng S, Xu M, et al. Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels. Oncotarget. 2018;9(3):3752–3764.
   PubMedGoogle Scholar
• Cai J, Yang F, Zhan H, et al. RNA m6A methyltransferase METTL3 promotes the growth of prostate cancer by regulating Hedgehog pathway. Onco Targets Ther. 2019;12:9143–9152.
   PubMed Web of Science ®Google Scholar
• Patil DP, Chen C-K, Pickering BF, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620):369–373.
   PubMed Web of Science ®Google Scholar
• Xiong W, Gao D, Li Y, et al. Genome-wide profiling of chemoradiation-induced changes in alternative splicing in colon cancer cells. Oncol Rep. 2016;36(4):2142–2150.
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen Z, Yong L. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol. 2018;148(2):368–374.
   PubMed Web of Science ®Google Scholar
• Luo Y, Sun Y, Li L, et al. METTL3 may regulate testicular germ cell tumors through EMT and immune pathways. Cell Transplant. 2020;29:963689720946653.
   PubMed Web of Science ®Google Scholar
• Zhang X, Flavell RA, Li HB. hnRNPA2B1: a nuclear DNA sensor in antiviral immunity. Cell Res. 2019;29(11):879–880.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Murphy K, Murphy BT, Boyce S, et al. Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer. Mol Oncol. 2018;12(9):1513–1525.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
   PubMed Web of Science ®Google Scholar
• Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol. 2016;28(8):383–391.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Bech E, Fehlings M, et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(7706):575–579.
   PubMed Web of Science ®Google Scholar